Comparative Pharmacology
Head-to-head clinical analysis: OXAZEPAM versus SERAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXAZEPAM versus SERAX.
OXAZEPAM vs SERAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to GABA-A receptor at benzodiazepine binding site, enhancing Cl- ion conductance and increasing inhibitory neurotransmission. Anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects.
SERAX (oxazepam) is a benzodiazepine that modulates GABA-A receptors, enhancing the inhibitory effect of GABA, leading to anxiolytic, sedative, and anticonvulsant effects.
10-30 mg orally 3-4 times daily; maximum 120 mg/day.
Oral: 5-10 mg twice daily; maximum 20 mg/day. Intravenous: 2-5 mg slow IV push, may repeat after 2 hours.
None Documented
None Documented
Terminal elimination half-life is 5-15 hours (mean 8 hours); no active metabolites, thus accumulation is minimal even with repeated dosing.
Clinical Note
moderateOxazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Oxazepam is combined with Fluticasone propionate."
Clinical Note
moderateOxazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Oxazepam."
Clinical Note
moderateOxazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Oxazepam."
Clinical Note
moderateOxazepam + Cyclosporine
Terminal elimination half-life is 8-15 hours (mean 12 hours) in adults; prolonged in renal impairment.
Renal (primarily as glucuronide conjugates, with less than 1% unchanged); biliary/fecal excretion is minimal.
Primarily renal (urinary) as unchanged drug (60-80%) and metabolites (20-40%); less than 5% fecal elimination.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Oxazepam."